Cell and tissue biology, 2026, Vol. 20, No. 6, P.

Supplementary Materials

CDK8/19 Inhibition Attenuates the Tolerance of Leukemia Cells to BCR-ABL1 Blockers in the Medium Conditioned by Bone Marrow Fibroblasts

A. M. Savin[1,*], D. P. Levchuk[1], A. S. Ilchenko[1], E. S. Ivanova [2,3], and A.A. Shtil [2,3]

[1] *Center for Molecular and Biological Technologies, ITMO University, Saint-Petersburg, 197101 Russia*

[2] *Blokhin National Medical Research Center of Oncology, Institute of Experimental Oncology and Carcinogenesis, Moscow, 115522 Russia*

[3] *National Research Nuclear University MEPhI, Institute of Cyber Intelligence, Moscow, 115409 Russia*

**e-mail: savin@itmo.ru*




Fig. S1. Quantitative analysis of cell viability (raw data of a typical flow cytometry experiment). A: Gating procedures excluded debris and cell doublets from the analysis; B: YO-PRO-1/PI staining experiments included negative (vehicle) and positive (cytarabine) controls to identify viable and dying cells. Histograms show data interpretation indicating that CDK8/19i sensitize cells to olverembatinib in the conditioned medium. C: SubG1 gating example with negative (vehicle) and positive (cytarabine) controls.




Fig. S2. Differential effects of bone marrow factors on vamotinib-induced K562 cell survival. Note the protection only in the medium conditioned by the HS-5 bone marrow-derived fibroblasts whereas cell adhesion to Matrigel or conditioning by human postnatal skin fibroblasts had no effect. Shown are IC_{50} values (mean ± SD of at least three biological measurements; resazurin assays).




Fig. S3. Cell cycle phase distribution after incubation of K562 cells with TKIs alone or in combinations with CDK8/19i (72 h). See text for details. Values are mean ± SD of at least three biological measurements.